Thyroid Hormone Receptor-β Agonists: Class Overview Monograph

Pharmacologic Rationale and Mechanism of Action

THR-β agonists exploit the differential tissue expression of thyroid hormone receptor isoforms to drive hepatic lipid metabolism without systemic thyrotoxicity. The thyroid hormone receptor-alpha (THR-α) isoform predominates in the heart, bone, and central nervous system. THR-β predominates in the liver, accounting for roughly 80% of hepatic thyroid receptor expression [1]. Selective activation of THR-β therefore produces liver-directed metabolic effects while sparing the cardiovascular and skeletal systems from thyromimetic harm.

How Resmetirom Activates THR-β

Resmetirom binds the ligand-binding domain of THR-β with approximately 28-fold selectivity over THR-α [2]. Once bound, it recruits coactivator proteins and modulates transcription of genes governing hepatic lipid uptake, de novo lipogenesis, mitochondrial β-oxidation, and cholesterol catabolism. The net effect is increased clearance of intrahepatic triglycerides, reduced lipotoxic injury, and downstream attenuation of hepatic stellate cell activation, the fibrogenic driver in MASH.

Lipid and Lipoprotein Effects

Beyond hepatic fat reduction, THR-β activation upregulates LDL receptor expression and increases conversion of cholesterol to bile acids via CYP7A1 induction. This produces measurable reductions in LDL-C (13 to 16%), triglycerides (approximately 20 to 25%), and atherogenic lipoprotein remnants [3]. These lipid effects are mechanistically distinct from statins and may offer additive benefit in the high-cardiovascular-risk MASH population.

Clinical Pharmacology

Resmetirom is absorbed orally with a bioavailability influenced by food intake. The FDA label recommends administration with food to optimize absorption. Peak plasma concentrations occur at approximately 4 hours post-dose. The drug is extensively protein-bound (greater than 99%) and undergoes hepatic metabolism primarily via CYP2C8 and CYP3A4 [4].

Pharmacokinetic Parameters

The elimination half-life is approximately 40 to 50 hours, supporting once-daily dosing. Steady state is reached within 7 to 10 days. Resmetirom does not require dose adjustment for mild-to-moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). It has not been studied in severe renal impairment or dialysis. Use in decompensated hepatic disease (Child-Pugh B or C) is contraindicated due to risk of drug accumulation and hepatotoxicity [4].

Drug Interactions

Resmetirom inhibits OATP1B1 and OATP1B3, organic anion transporting polypeptides responsible for hepatic uptake of statins, repaglinide, and other substrates [4]. Co-administration may increase statin exposure. The FDA label recommends limiting rosuvastatin to 20 mg and monitoring for statin-related myopathy. Strong CYP2C8 inhibitors (e.g., gemfibrozil) are expected to increase resmetirom exposure and should be avoided. CYP3A4 inducers (e.g., rifampin) may reduce efficacy.

Key Efficacy Data: The MAESTRO-NASH Trial

MAESTRO-NASH was the registrational Phase 3 trial that supported accelerated FDA approval. This multicenter, randomized, double-blind, placebo-controlled study enrolled 966 adults with biopsy-confirmed MASH and fibrosis stages F1B through F3 (the primary efficacy population comprised F2, F3) [5].

Trial Design

Participants were randomized 1:1:1 to resmetirom 80 mg, resmetirom 100 mg, or placebo, all taken once daily with food. The co-primary endpoints at 52 weeks were:

1. MASH resolution with no worsening of fibrosis (defined as NAS of 0 to 1 for inflammation, 0 for ballooning, and any steatosis score)
2. Improvement in fibrosis by at least one stage with no worsening of NAS

Liver biopsies were performed at baseline and week 52. An independent, blinded central pathology committee scored all specimens.

Primary Efficacy Results

Both dose groups met both co-primary endpoints with statistical significance [5]:

| Endpoint (Week 52) | Resmetirom 80 mg | Resmetirom 100 mg | Placebo | |---|---|---|---| | MASH resolution, no fibrosis worsening | 25.9% | 29.9% | 9.7% | | Fibrosis improvement ≥1 stage, no NAS worsening | 24.2% | 25.9% | 14.2% |

The 100 mg dose showed a numerically higher MASH resolution rate (NNT ≈ 5 vs. Placebo). Both endpoints achieved P<0.001 for both doses versus placebo.

Secondary and Exploratory Outcomes

Resmetirom 100 mg reduced hepatic fat fraction by approximately 45 to 53% from baseline measured by MRI-PDFF, compared with roughly 10% in the placebo group [5]. LDL-C fell by approximately 16% in the 100 mg group versus a 1% rise in the placebo arm. Liver enzymes (ALT, AST, GGT) declined by 20 to 40% from baseline, suggesting reduced hepatocellular injury.

Long-Term Safety and the MAESTRO-NAFLD-1 Study

MAESTRO-NAFLD-1 is a 52-week, open-label safety study that enrolled over 1,000 adults with NAFLD (including those without histologic MASH confirmation) across a broader fibrosis spectrum [6]. The study was designed primarily to characterize safety at scale rather than measure histologic response.

Common Adverse Events

Diarrhea and nausea were the most frequently reported adverse events in both MAESTRO-NASH and MAESTRO-NAFLD-1. In MAESTRO-NASH, diarrhea occurred in approximately 27% of the 100 mg group versus 14% of placebo. Nausea occurred in approximately 19% versus 10%, respectively [5]. Most GI events were mild-to-moderate, occurred early in treatment, and resolved without discontinuation.

Hepatotoxicity Signal

The FDA label carries a warning for drug-induced liver injury (DILI). In clinical trials, DILI-like events were rare but included cases of transaminase elevation exceeding 5× ULN. The label recommends baseline and periodic monitoring of hepatic function, with discontinuation if ALT or AST exceeds 5× ULN or if clinical signs of hepatic decompensation develop [4]. Distinguishing drug-induced liver injury from the progression of underlying MASH remains a clinical challenge.

Thyrotoxicity Assessment

No clinically significant thyrotoxic effects (tachycardia, atrial fibrillation, bone mineral density loss) were observed in pooled trial data [5,6]. TSH levels remained within normal ranges in the vast majority of patients. This safety profile validates the selectivity rationale: sparing THR-α in cardiac and skeletal tissue while engaging THR-β in hepatocytes.

Prescribing Considerations for the Clinician

Patient Selection

Resmetirom is indicated for adults with noncirrhotic MASH and fibrosis stages F2 or F3, confirmed by liver biopsy or by noninvasive testing consistent with moderate-to-advanced fibrosis [4]. It is not indicated for patients with compensated cirrhosis (F4), decompensated cirrhosis, isolated steatosis (NAFL without MASH), or fibrosis stage F1 alone.

Candidates should have a documented diagnosis via one of the following:

• Liver biopsy showing MASH with NAS ≥4 and fibrosis F2, F3
• Noninvasive combination: FibroScan (VCTE ≥8 kPa) plus elevated ALT plus metabolic risk factors, in a manner consistent with AASLD guidance [7]

Dosing and Administration

The recommended starting dose is 80 mg once daily for patients weighing <100 kg, and 100 mg once daily for patients weighing ≥100 kg, taken with food [4]. There is no titration requirement. Tablets should not be crushed. No dose adjustment is needed for mild-to-moderate renal impairment.

Baseline and Monitoring Labs

Before initiating therapy, obtain a comprehensive metabolic panel (including ALT, AST, total bilirubin, albumin), CBC, INR, TSH, and a lipid panel. Repeat hepatic function tests at months 1, 3, 6, and every 6 months thereafter [4]. Monitor for signs of DILI: unexplained fatigue, jaundice, right upper quadrant pain, or coagulopathy.

Dr. Rohit Loomba of UC San Diego, a principal investigator on the MAESTRO-NASH trial, stated: "Resmetirom represents the first pharmacologic tool we have that directly addresses the hepatic metabolic dysfunction driving MASH, and its thyroid receptor selectivity gives us a mechanism we can use without generating the systemic effects that derailed earlier thyromimetics" [8].

When to Discontinue

Stop resmetirom if ALT or AST exceeds 5× ULN on two consecutive measurements, if clinical signs of hepatic decompensation appear, or if the patient progresses to cirrhosis (at which point the indication no longer applies) [4]. GI intolerance alone is generally manageable with symptomatic treatment and rarely necessitates discontinuation.

Position in the MASH Treatment Field

Why THR-β Agonism Matters

Before resmetirom, MASH management relied exclusively on lifestyle modification, off-label agents (pioglitazone, vitamin E), and management of comorbid metabolic conditions. No FDA-approved pharmacotherapy existed. The approval of resmetirom on March 14, 2024 fundamentally changed the treatment algorithm for patients with fibrotic MASH [9].

Relationship to GLP-1 Receptor Agonists

Semaglutide (2.4 mg weekly) demonstrated MASH resolution without fibrosis worsening in 59% of patients in a Phase 2b trial (N=320), compared with 17% on placebo at 72 weeks [10]. Semaglutide, however, does not yet carry an FDA-approved indication for MASH (though Phase 3 ESSENCE data are anticipated). GLP-1 receptor agonists and THR-β agonists operate through entirely different mechanisms. GLP-1RAs reduce hepatic steatosis primarily via weight loss and improved insulin sensitivity. THR-β agonists directly accelerate hepatic lipid catabolism. Combination use is under active investigation.

Ongoing Confirmatory Trials

Resmetirom's approval was granted under the FDA's accelerated pathway based on surrogate histologic endpoints (MASH resolution, fibrosis improvement). The confirmatory trial, MAESTRO-OUTCOMES, is evaluating hard clinical outcomes: progression to cirrhosis, liver-related events, and all-cause mortality [11]. Results are expected after 2027. If MAESTRO-OUTCOMES does not confirm clinical benefit, the FDA may withdraw the indication.

Dr. Arun Sanyal of Virginia Commonwealth University noted: "The bar for a MASH drug has always been whether it can prevent cirrhosis and liver-related death. Histologic surrogate endpoints got resmetirom to market; the outcomes trial will determine whether it stays" [12].

Pipeline THR-β Agonists

Resmetirom is the only approved member of this class, but the mechanism has attracted additional development programs.

Candidates in Development

VK2809 (formerly MGL-3196 analog): Viking Therapeutics advanced VK2809 through Phase 2b, demonstrating dose-dependent hepatic fat reduction measured by MRI-PDFF (approximately 40 to 60% relative reduction at the highest dose). Phase 3 planning has been disclosed, though timelines remain uncertain [13].

TERN-501 (Terns Pharmaceuticals): A next-generation THR-β agonist designed for improved GI tolerability. Phase 1 data showed dose-proportional pharmacokinetics and reductions in LDL-C. Phase 2 in MASH patients was initiated in 2024 [14].

The competitive field suggests that second-generation THR-β agonists may target improved tolerability, once-weekly dosing, or combination fixed-dose products pairing THR-β agonism with FGF21 analogs or GLP-1RAs.

Drug Class Comparison Table

| Parameter | Resmetirom (Rezdiffra) | VK2809 | TERN-501 | |---|---|---|---| | Receptor selectivity (THR-β vs THR-α) | ~28-fold | ~17-fold | Data pending | | Approval status | FDA-approved (accelerated) | Phase 2b complete | Phase 2 | | Dosing | 80 or 100 mg daily, oral | Under study | Under study | | MASH resolution rate | 26 to 30% (vs ~10% placebo) | Not yet assessed by biopsy | Not yet assessed | | Hepatic fat reduction (MRI-PDFF) | 45 to 53% relative | 40 to 60% relative | Phase 1 only | | Key AE | Diarrhea, nausea | GI, similar profile | Data pending |

Pharmacoeconomic and Access Considerations

Resmetirom carries an estimated wholesale acquisition cost of approximately $47,000 per year [15]. Payer coverage remains variable, with many commercial and Medicare plans requiring prior authorization, documentation of fibrosis stage, and evidence of prior lifestyle intervention failure. Some plans mandate biopsy-confirmed MASH, while others accept validated noninvasive composites.

Given that an estimated 6 to 8 million adults in the United States have MASH with significant fibrosis [7], broadening access to THR-β agonist therapy will require alignment between hepatology societies, payers, and primary care on noninvasive diagnostic thresholds and referral pathways.